Genmab and Biontech to advance lung cancer drug acasunlimab to Phase III

Acasunlimab was formerly known as Gen1046.
Resultater af fase 2-studie med lægemiddelkandidaten acasunlimab til behandling af lungekræft er ifølge udviklingschef hos Genmab opmuntrende. | Photo: Medwatch/photo by Ulrich Quistgaard
Resultater af fase 2-studie med lægemiddelkandidaten acasunlimab til behandling af lungekræft er ifølge udviklingschef hos Genmab opmuntrende. | Photo: Medwatch/photo by Ulrich Quistgaard

Genmab and Biontech presented data from a Phase II study of acasunlimab in lung cancer at ASCO in Chicago.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading